Onkologie. 2016:10(1):20-24 | DOI: 10.36290/xon.2016.002
New WHO classification of lung tumours
- Klinika pneumologie a ftizeologie FN Plzeň
The review article presents detailed information on the new classification of lung tumours issued by the World Health Organization.
In comparison with the previous 2004 classification, there have been numerous changes that are dealt with in detail
and that include, among other things, integration of molecular genetic testing and morphological examination with respect
to a more precise diagnosis when molecular targeted therapy is indicated. The new classification also includes terminology
changes as well as the current criteria for morphological evaluation of findings of small biopsy and cytology and in resected
tumour samples. Also, the diagnostic criteria for adenocarcinoma in situ and minimally invasive lung adenocarcinoma have
been newly defined.
Keywords: morphology of lung tumours, WHO classification, molecular genetic testing, diagnostic terminology of lung tumours, lung biopsy
Published: March 1, 2016 Show citation
References
- World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and Heart. Edited by Travis WD, Brambilla E, Müller-Hermelink HK and Harris CC. Lynon, France, 2003.
- WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Edited by Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG: Lyon, France, 2014.
- Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell ChA, Tsao MS and Wistuba I. The 2015 World Health Organization Classification of Lung Tumors. Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. Journal of Thoracic Oncology 2015, Vol. 10, Number 9, 1243-1260.
Go to original source... 
Go to PubMed... - Practical considerations on diagnosis of non-small cell lung cancer from small samples. Making science personal. Lilly Oncology 2012, 80 pages.
- Di Giorgio A, Mingazzini P, Sammartino P, Canavese A, Arnone P, Scarpini M. Host defense and survival in patients with lung carcinoma. Cancer 2000; 89: 2038-45. Go to original source...
- Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macr? L, Daniele L, Oliaro A. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg. 2009 Feb; 87(2): 365-371; discussion 371-2. doi: 10.1016/j.athoracsur.2008.10.067. Go to original source... Go to PubMed...
- Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology. 2009 Sep;55(3):301-12. doi: 10.1111/j.1365-2559.2009.03379.x. Go to original source... Go to PubMed...
- Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, Lebecque S, Fridman WH, Cadranel J. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008 Sep 20;26(27):4410-7. doi: 10.1200/JCO.2007.15.0284. Go to original source... Go to PubMed...
- Fridman WH, Pag?s F, Saut?s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012 Mar 15;12(4):298-306. doi: 10.1038/nrc3245. Go to original source... Go to PubMed...
- Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s. Go to original source... Go to PubMed...
- Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297-339. Go to original source... Go to PubMed...
- Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007 Jul;27(1):111-22. Epub 2007 Jul 12. Go to original source... Go to PubMed...
- Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5. Epub 2007 Feb 21. Go to original source... Go to PubMed...